Search research articles
Contact Us
Filters
Showing results (51-60 of 80) with videos related to
Page
of 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2025
Concordance between tumor tissue and plasma DNA genotyping in the NCI-MATCH trial (EAY131)
Mohamed A Gouda, Filip Janku, Ying Yuan, et al.
JCO Precision Oncology
|
December 12, 2024
Phase II Study of Sunitinib in Tumors With <i>c-KIT</i> Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V
Lilian T Gien, Zihe Song, Andrew Poklepovic, et al.
JCO Precision Oncology
|
September 19, 2024
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I)
Margaret E Macy, Rajen Mody, Joel M Reid, et al.
JCO Precision Oncology
|
July 10, 2024
Phase II Trial of Afatinib in Patients With <i>EGFR</i>-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A
Scott N Gettinger, Zihe Song, Karen L Reckamp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2022
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial
Olive S Eckstein, Carl E Allen, P Mickey Williams, et al.
JCO Precision Oncology
|
June 27, 2024
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
Kieuhoa T Vo, Amit J Sabnis, P Mickey Williams, et al.
JCO Precision Oncology
|
January 14, 2026
Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i><sup><i>V600E</i></sup> Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H
April K S Salama, Victoria Wang, Erin R Macrae, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2022
Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
D Williams Parsons, Katherine A Janeway, David R Patton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2024
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C
Mark H O'Hara, Opeyemi Jegede, Mark A Dickson, et al.
JCO Precision Oncology
|
September 19, 2024
Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D
Theodore W Laetsch, Kathleen Ludwig, P Mickey Williams, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 80) with videos related to
Sort By:
Page
of 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2025
Concordance between tumor tissue and plasma DNA genotyping in the NCI-MATCH trial (EAY131)
Mohamed A Gouda, Filip Janku, Ying Yuan, et al.
JCO Precision Oncology
|
December 12, 2024
Phase II Study of Sunitinib in Tumors With <i>c-KIT</i> Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V
Lilian T Gien, Zihe Song, Andrew Poklepovic, et al.
JCO Precision Oncology
|
September 19, 2024
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I)
Margaret E Macy, Rajen Mody, Joel M Reid, et al.
JCO Precision Oncology
|
July 10, 2024
Phase II Trial of Afatinib in Patients With <i>EGFR</i>-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A
Scott N Gettinger, Zihe Song, Karen L Reckamp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2022
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial
Olive S Eckstein, Carl E Allen, P Mickey Williams, et al.
JCO Precision Oncology
|
June 27, 2024
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
Kieuhoa T Vo, Amit J Sabnis, P Mickey Williams, et al.
JCO Precision Oncology
|
January 14, 2026
Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i><sup><i>V600E</i></sup> Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H
April K S Salama, Victoria Wang, Erin R Macrae, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2022
Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
D Williams Parsons, Katherine A Janeway, David R Patton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2024
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C
Mark H O'Hara, Opeyemi Jegede, Mark A Dickson, et al.
JCO Precision Oncology
|
September 19, 2024
Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D
Theodore W Laetsch, Kathleen Ludwig, P Mickey Williams, et al.
Page
of 8